The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.l Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.y Progression, acceleration or exacerbation of preexisting ILD/fibrosis

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.b ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.e Transfusion-related acute lung injury (TRALI) (May cause ARDS)

II. Pulmonary edema - Acute lung injury - ARDS

II.f Hypoxemia, low oxygen saturation (may occur in isolation)

II. Pulmonary edema - Acute lung injury - ARDS

II.h Overload pulmonary edema (including posttransfusional (TACO))

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

VI. Pulmonary vasculopathy

VI.a Pulmonary embolism - Venous thrombosis/thromboembolism

VI. Pulmonary vasculopathy

VI.i Acute pulmonary hypertension

VI. Pulmonary vasculopathy

VI.n Crystal pulmonary embolism

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.a Angioedema (may cause UAO, asphyxia and death)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.d Metabolic acidosis (incl. lactic acidosis/-gap). May cause hyperpnea/dyspnea

XI. Miscellaneous

XI.n Neutropenia, agranulocytosis (w/wo infection/sepsis)

XII. Cardiovascular involvement / toxicity

XII.j Myocardial stunning

XII. Cardiovascular involvement / toxicity

XII.n Cardiovascular collapse - Cardiogenic shock - Hypotension

XV. Pathology

XV.g Path: Alveolar hemorrhage (see also IIIa)

XV. Pathology

XV.w Path: Pulmonary edema (see also II/IIa)

XV. Pathology

XV.aj Path: Cholesterol crystal embolism

XV. Pathology

XV.at Path: Pulmonary capillary granulocyte sequestration

XVI. Imaging

XVI.d Imaging: Alveolar opacities or haze with a batwing or butterfly distribution

XVII. Infections & related conditions

XVII.ad Systemic infection (transmitted)